Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Brian Moore who wrote (17682)	3/19/1998 9:12:00 AM
From: Allan Harris	Read Replies (1) \| Respond to of 32384

>I have pretty much been echoing O'Neil's main strategy in my posts. It would be interesting to see how O'Neil's mutual fund was doing, the one run O'Neil and his sidekick, David Ryan. I believe it is called "New USA Fund." Unfortunately, I could only find performance figures through the first quarter of 1997, where the fund had lost 14% for three months, lost 15% for six months and was up 0.7% for one year...this is in the face of a stunning bull market for all of the above three periods. There is a saying something like, "Those who can, do....those who can't, teach." Without current figures on their fund, it's hard to say if it applies here, so I'll reserve judgment............kind of. As for LGND, if they had steady earnings and approved products, the stock would not be at it's current market cap. LGND's price reflects some market risk, that earnings and products won't come, at least in a timely fashion, which seems to be dwarfed by the potential reward as the company matures. For me, it's a simple bet, with attractive risk:reward parameters. Recent chart patterns (posted here) caused me to double up. Allan, King of France